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Abstract
Background: Epigenetic mechanisms provide an interface between environmental factors and the genome and
are known to play a role in complex diseases such as obesity. These mechanisms, including DNA methylation,
influence the regulation of development, differentiation and the establishment of cellular identity. Here we employ
two approaches to identify differential methylation between two white adipose tissue depots in obese individuals
before and after gastric bypass and significant weight loss. We analyse genome-wide DNA methylation data using
(a) traditional paired t tests to identify significantly differentially methylated loci (Bonferroni-adjusted P ≤ 1 × 10−7)
and (b) novel combinatorial algorithms to identify loci that differentiate between tissue types.
Results: Significant differential methylation was observed for 3239 and 7722 CpG sites, including 784 and 1129
extended regions, between adipose tissue types before and after significant weight loss, respectively. The vast
majority of these extended differentially methylated regions (702) were consistent across both time points and
enriched for genes with a role in transcriptional regulation and/or development (e.g. homeobox genes). Other
differentially methylated loci were only observed at one time point and thus potentially highlight genes important
to adipose tissue dysfunction observed in obesity. Strong correlations (r > 0.75, P≤ 0.001) were observed between
changes in DNA methylation (subcutaneous adipose vs omentum) and changes in clinical trait, in particular for CpG
sites within PITX2 and fasting glucose and four CpG sites within ISL2 and HDL. A single CpG site (cg00838040,
ATP2C2) gave strong tissue separation, with validation in independent subcutaneous (n = 681) and omental (n = 33)
adipose samples.
Conclusions: This is the first study to report a genome-wide DNA methylome comparison of subcutaneous abdominal
and omental adipose before and after weight loss. The combinatorial approach we utilised is a powerful tool for
the identification of methylation loci that strongly differentiate between these tissues. This study provides a solid
basis for future research focused on the development of adipose tissue and its potential dysfunction in obesity,
as well as the role DNA methylation plays in these processes.
Keywords: Adipose, Biomarkers, DNA methylation, Graph-theoretical algorithms, Epigenetics, Obesity
* Correspondence:
Donia.Macartney-Coxson@esr.cri.nz; langston@tennessee.edu
1Biomarkers Group, Institute of Environmental Science and Research (ESR),
Wellington 5022, New Zealand
4Department of Electrical Engineering & Computer Science, University of
Tennessee, Knoxville, TN 37996-2250, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Macartney-Coxson et al. Clinical Epigenetics  (2017) 9:48 
DOI 10.1186/s13148-017-0344-4
Background
Epigenetic mechanisms provide an interface between
environmental factors and the genome and are known to
play a role in complex diseases such as obesity [1–3].
These mechanisms, including DNA methylation, influence
the regulation of development, differentiation and the
establishment of cellular identity (for reviews, see [4, 5]).
There is increasing evidence that many complex diseases
such as obesity, type 2 diabetes and coronary heart disease
have at least some origins in early life—that is, the
‘developmental origin of disease’ hypothesis. This
hypothesis states that such diseases result from an
imbalance between the in utero and/or early life
environment and that experienced later in life [6–8].
Thus, the importance of epigenetic mechanisms in
development, and their significant role in complex
diseases, heightens both their promise as potential
diagnostic markers and their potential to provide new
insights into disease biology (for a review in the
context of type 2 diabetes, see [9]).
There are two main types of white adipose tissue in
humans, subcutaneous and visceral (including omen-
tum), with different depots throughout the body, for in-
stance, abdominal and gluteal depots of subcutaneous
adipose. Higher levels than expected of brown adipose
tissue depots, rich in mitochondria and once thought to
be found only in early development, have more recently
been identified in human adults [10–12]. Furthermore,
‘browning’ or ‘beiging’ of white adipose tissue can occur
[13, 14]. These various adipose tissues have distinct
structural and biochemical properties [15–17], and both
body fat distribution and function influence metabolic risk
[18–25]. Gene expression analyses originally highlighted
the potentially different developmental origins of subcuta-
neous and visceral adipose tissue [17, 26–28], with recent
evidence suggesting a mesothelial origin for visceral adi-
pose [29]. Furthermore, DNA methylation differences
have been reported between subcutaneous abdominal and
subcutaneous gluteal adipose tissue [30]. A recent study
also reported genome-wide promoter methylation and
transcriptome analysis of subcutaneous and omental
adipose in obese vs lean individuals [31].
We previously performed DNA methylation analyses
of paired subcutaneous and omental adipose from obese
individuals undergoing gastric bypass, seeking to identify
within-tissue differences before and after significant
weight loss (>27% initial weight loss) [32]. In the current
study, we perform inter-adipose tissue (subcutaneous
adipose vs omentum) comparisons, hypothesising that
given the different developmental origins of these
tissues, (a) changes in DNA methylation before and after
significant weight loss could reveal new insights into
obesity biology and the role tissue development might
play in this, and (b) this data would provide an excellent
‘proof of principle’ on which to test a combinatorial
approach for identifying loci that differ.
Results
Differential methylation between subcutaneous and
omental adipose at specific CpG loci
We performed paired t tests to identify differentially
methylated CpG loci, assayed by the Illumina 450K
BeadChip, between subcutaneous abdominal and omen-
tal adipose independently at two time points, before and
after significant weight loss. This analysis was carried
out on DNA methylation data previously obtained from
15 morbidly obese individuals before and after gastric by-
pass [32]. We identified 3239 (1294 annotated genes) and
7722 (3164 annotated genes) significant differentially
methylated CpG loci (Bonferroni-adjusted P ≤ 1 × 10−7)
between the two adipose tissue depots before and after
weight loss, respectively. The majority of these CpG sites
were less methylated in subcutaneous than in omental
adipose, with only 23.1 and 18.8% showing relative hyper-
methylation in the subcutaneous depot before and after
weight loss, respectively. Table 1 provides an overall sum-
mary, and Table 2 shows details on the top 20 ranking
sites for each time point. The total number of CpG loci
that overlapped between the analyses at the two time
points was 2077 (813 annotated genes); 966 of these CpG
sites showed a larger methylation difference (Δbeta) of at
least 5% between the adipose tissue depots after weight
loss than before. All sites passing the Bonferroni adjust-
ment threshold are available in Additional files 1 and 2
(sites which overlap between the two time points are
indicated).
Given the suggested mesothelial origin of visceral adi-
pose, we interrogated the list of significant differentially
methylated loci for CpG sites located within genes
related to this. In particular, we looked at WT1 (Wilms
tumour 1), whose role in the development and mesothe-
lial origin of visceral adipose was recently recognised
[29, 33]. We also observed differential methylation in
two mesothelial markers, MSLN (the gene encoding
mesothelin) and UPK3b [34], as well as MSLNL
(mesothelin-like). Differential methylation within MIER2
(mesoderm induction early response 1, family member 2)
was also seen in the after weight loss analysis (Table 3).
Extended regions of differential methylation between
subcutaneous and omental adipose
To investigate further the DNA methylome differences
between subcutaneous and omental adipose, we looked
for extended differentially methylated regions (DMRs)
using the DMRcate package [35] in R. A total of 784 and
1126 DMRs were identified before and after weight loss,
respectively, that passed a combined adjusted P (Stoeffler)
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threshold of 0.05. Of these DMRs, 706 overlapped
between the comparisons. Notably, the top 3 ranking
DMRs in terms of significance (Stoeffler P value)
were located on chromosome 2 within regions to
which homeobox genes mapped: EN1 (DMR: Chr2:11
9602212-119617128, Fig. 1), HOXD3 (DMR: Chr2:17
7021702-177030228) and HOXD4:miR10b (Chr2:1770
12117-177017797). The fourth was located in homeo-
box gene PITX2 on chromosome 4 (Chr4:111549880-
111555503). A DMR was also observed at both time
points in MSLN (Chr16:809476-811744, before weight
loss mean Δbeta = 0.059, after weight loss mean
Δbeta = 0.076). Details of all significant DMRs
identified are in Additional files 3 and 4.
To explore the potential biological significance of
these observations, we performed enrichment analyses
for the genes mapping to significant DMRs, setting
Bonferroni P ≤ 0.05 for significant enrichment. Three
gene sets were submitted for analyses to facilitate an
exploration of biological functions: (i) those potentially
‘hard-wired’ to the tissue types, that is, genes mapping
to significant DMRs identified in both comparisons,
n = 385; (ii) those unique to the tissue types before
gastric bypass and weight loss, that is, genes mapping
to unique DMRs, n = 30; and (iii) those unique to the
tissue types after gastric bypass and weight loss, that
is, genes mapping to unique DMRs, n = 256. A full
list of significant pathways identified for all three can
be found in Additional files 5, 6 and 7.
Significant DMRs observed between tissues at both time points
Enrichment was observed for GO Molecular Function
pathways related to DNA binding, transcription and/or
transcriptional regulation, for GO Biological Processes
involved in development/morphogenesis and for homeo-
domain/homeobox domain proteins and PAX genes.
Gene targets for miR374 and miR10 were also enriched.
We also performed pathway analysis on the 85 overlap-
ping DMRs (mapping to annotated genes) which showed a
greater difference in the mean Δmethylation between the
two tissues after weight loss compared to before. As above,
enrichment was observed for pathways related to DNA
binding, transcription and/or transcriptional regulation,
and involved in development/morphogenesis as well as for
homeodomain/homeobox domain proteins. Domain
analysis also revealed enrichment for Sim1 and Sim2, and
TBX genes (TBX15, TBX4, TBX5). See Additional file 8 for
a full list of significant pathways identified.
Significant DMRs unique to the subcutaneous vs omental
adipose comparison before weight loss
Enrichment was observed for GO Biological Processes
related to dendrite function, specifically three genes
(SYT4, CPNE6, NEDD4L) and GO Cellular Component
pathways related to the synapse. DGALP2 was significant
for protein interactions, and enrichment of gene targets
for miR141 and miR200a was observed. Loci in which
significant DMRs were only observed for the before
weight loss comparison included HOXD8, HOTAIRM1
and HSD17B1.
Significant DMRs unique to the subcutaneous vs omental
adipose comparison after weight loss
Enrichment was observed for GO Molecular Function
pathways involved in DNA binding, notably the retinoic
acid receptor response element (GO: 0044323) and GO
Biological Processes including cell adhesion, develop-
ment/morphogenesis, and immune cell activity and
differentiation (notably T cell function). No enrichment
for protein interactions or miRNA targets was seen.
Genes in which significant DMRs were only observed
for the after weight loss comparison included HOXB5,
TBX5, MTOR, RPTOR and HSD17B14.
Identification of correlations between differential tissue
methylation and clinical parameters
We reasoned that significant differentially methylated sites
which overlapped between the two time points might be
indicative of ‘hard-wiring’ in terms of development/
differentiation of the adipose depots and that those
with a greater difference at one time point might pro-
vide insight into disease pathology. Concentrating on
Table 1 Summary of significantly differentially methylated CpG sites identified in subcutaneous vs omental adipose tissue before
and after weight loss
Total CpG sites CpG sites with
Δ beta≥ 5%
CpG sites with
Δ beta≥ 10%
CpG sites with
Δ beta≥ 20%
CpG sites with
Δ beta≥ 50%
Before weight loss 3239
+ Δbeta 2491 2400 1667 260 1
− Δbeta 748 748 682 275 0
After weight loss 7722
+ Δbeta 6274 6193 4774 1137 7
− Δbeta 1448 1446 1340 666 3
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those sites (n = 966) which showed a greater methylation
difference after weight loss, we performed Pearson’s
correlation analyses between the Δbeta (subcutaneous
adipose vs omentum) and Δclinical trait (clinical trait
before vs after weight loss). Filtering for P ≤ 0.001, be-
fore weight loss, we observed seven associations. Δbeta
at one site (cg21475076) was correlated with ΔBMI
and Δkg (r = 0.84, r = 0.86, respectively) with Δbeta at
other sites correlated with changes in fasting insulin
(cg14954582, r = −0.90; cg04757806, r = 0.83), LDL
(cg1384319, r = −0.80) and cholesterol (cg19640526, r =
−0.79; cg01020413, r = 0.78). Only one of the sites,
cg04757806, mapped to an annotated gene, FUT4.
After weight loss, we observed 75 correlations passing a
P ≤ 0.001 threshold. Notably, the majority of these (64/75)
were with ΔHDL, including strong correlations between
Δbeta and ΔHDL for four sites within 1061 bp of each
other in ISL2 (cg06375967, cg17446010, cg12984729,
cg08307030 with r = −0.78, −0.83, −0.87, −0.86, respec-
tively). Δbeta at two CpG sites in PITX2 was correlated
with Δfasting glucose (cg268311119 and cg24005685,
r = −0.89 and −0.79, respectively), and one of these
was also correlated with Δfasting insulin (cg24005685,
r = −0.89). Details of all sites passing filtering at P ≤ 0.001
can be found in Additional file 9.
Identification of tissue differentiation markers
We also analysed the DNA methylation data using a
combinatorial approach, in an effort to complement and
extend more standard statistical differential (paired t test)
techniques. Having originally applied this approach to
gene expression data [36], here we aimed to identify signa-
ture(s) predictive of tissue type at the two time points
(before and after gastric bypass-associated weight loss).
The subcutaneous abdominal vs omental adipose tissue
comparisons were applied independently (before and after
Fig. 1 Plot illustrating a DMR located in EN1. Samples from the after gastric bypass and weight loss analyses (OP2) are shown. The chromosomal
and gene architecture is shown with relative methylation illustrated below for each subcutaneous adipose (AB) and omental (OM) sample from
hyper- (red) through hypomethylation (blue). Average methylation (mean beta value) is plotted for each tissue, omentum (OAT, green) and
subcutaneous adipose (SAT, blue), at the bottom
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gastric bypass-associated weight loss). Initial analyses of
the different adipose tissues before weight loss revealed
4900 CpG sites (mapping to 2309 genes) that passed filter-
ing and had positive merit scores (such a score estimates a
site’s relative ability to distinguish among sample tissue
classes) (Additional file 10). Figure 2a presents the distri-
bution of inter-sample paired comparison scores using
this panel of 4900 CpG sites, which demonstrates their
ability to give appealing, but not complete, separation of
the tissues. An equivalent analysis of the tissues after
weight loss identified 8624 CpG sites (mapping to 4066
genes) with positive merit scores (Additional file 11) that
again gave an attractive separation of tissues (Fig. 2b). The
total number of CpG sites that overlapped between the
two analyses was 1022. Details of the top 10 ranking sites
for each analysis are presented in Table 4.
Initial analysis identified all sites with positive merit
scores and then selected sites that best covered others.
Given that an ideal, and potentially cost-effective,
biomarker panel includes the least number of markers
required for robust differentiation between groups, we
investigated the discriminatory power of a reduced num-
ber of sites for each time point. A robust differentiation
between tissues was identified for the top 10 ranking
sites from the before weight loss analysis (Fig. 2c). Sepa-
ration of the two tissues using the top 10 ranking sites
from the after weight loss analysis provided better
discrimination than the 8624 sites identified in the first-
pass, but not complete, partitioning (Fig. 2d).
We then reduced the number of sites to one; the top
site from the before weight loss comparison did not
perform as well (Fig. 2e), whereas full discriminatory
power was seen for the top site from the after weight
loss analysis (Fig. 2f ).
Given the striking utility of a single site (cg00838040) to
discriminate fully the two tissue types after weight loss, we
investigated this further. This CpG loci is within an intron
of ATP2C2. Visualisation of the region surrounding the
CpG in the UCSC Genome Browser (http://genome.ucs-
c.edu/) revealed that it sits within a region protected by
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Fig. 2 Histograms presenting the inter-sample scores for all sites passing initial analysis (a, b), the top 10 ranking sites (c, d) and the top ranking
site (e, f), before (a, c, e) and after (b, d, f). Inter-sample scores were generated for all sample pairwise comparisons for omentum (OM) and
subcutaneous abdominal adipose (AB). Same tissue comparisons (i.e. OM vs OM and AB vs AB) would need to score more highly than
contra-tissue comparisons (OM vs AB) for a useful discriminatory panel of markers. An ideal panel would show no overlap between
same and contra-group comparisons
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transcription factor CEBPB (Chr16:84446744-84447019,
CpG at Chr16:84446919, genome build 37/hg19) as indi-
cated by ENCODE ChipSeq analyses.
Given the paired nature of the samples (i.e. subcutane-
ous and omental adipose from the same individuals) in
the analysis, we retained probes annotated to contain
SNPs (as per Illumina manifest). Therefore, we then
investigated whether any SNPs were adjacent to
cg00838040 in ATP2C2. SNP rs12102757 (C/T) is
located 35 bases from the CpG site interrogated by
cg00838040 and 3 bases downstream of the CEBPB
binding motif. This SNP has a mean minor allele fre-
quency of 0.282, with a range 0.168–0.511 depending on
the population examined (www.ensembl.org, 1000 ge-
nomes phase III). No prior associations for rs12102757
were observed with obesity or related phenotypes when
searching the latest build of the GWAS (genome-wide
association study) catalog (https://www.ebi.ac.uk/gwas).
We also looked at ATP2C2 RNA abundance on the GTEx
Portal (Genotype-Tissue Expression project, www.gtex-
portal.org) and observed minimal expression in subcuta-
neous adipose and omentum. When we investigated the
possibility of relationships between Δbeta cg00838040 and
changes in clinical traits using a Pearson’s correlation ana-
lysis, we did not observe any. Our previous study which
investigated intra-tissue methylation differences before
and after weight loss did not observe any correlations with
clinical parameters either [32].
As for differential methylation, we examined the lists
of 2309 and 4066 genes, respectively, in the before and
after weight loss analyses to see whether they contained
loci with a reported role in the mesothelial origin of
visceral adipose tissue. We observed differential
methylation within WT1 at both time points and
within MSLN, MSLN1, UPK3B and MIER2 after
weight loss; CpG sites in both MSLN1 and MIER2
were also identified in the before weight loss analysis
(see Table 3).
Validation of tissue differentiation markers
We performed a technical validation of our observations
using pyrosequencing of robust tissue discriminators
from each analysis, that is, the top 10 ranking sites from
the before weight loss analysis and the top site from the
after weight loss analysis (Table 4, Figs. 2c and 1e). This
revealed an excellent agreement between the two
Table 4 Top10 CpG sites by biomarker ranking that differentiate subcutaneous and omental adipose tissue at each time point
Illumina probe ID AB mean beta
(±standard deviation)
OM mean beta
(±standard deviation)
UCSC gene
nameab
CpG site chromosome
and positionb
Traditional analysis
rank by P value
Traditional analysis rank
by absolute Δbeta
Before weight loss analysis
cg02245004 0.12 (±0.08) 0.64 (±0.11) Intergenic 15:76634887 318 1
cg03923561 0.45 (±0.07) 0.04 (±0.02) HOXC4 12:54447220 12 5
cg22747076 0.42 (±0.09 0.02 (±0.02) HOXC4 12:54447873 31 7
cg09400037 0.42 (±0.06) 0.82 (±0.07) Intergenic 16:84822801 102 6
cg24376776 0.03 (±0.01) 0.33 (±0.03) Intergenic 10:101297245 1 62
cg11797364 0.59 (±0.1) 0.97 (±0.02) Intergenic 6:436969 329 14
cg17496661 0.65 (±0.08) 0.99 (±0.01) Intergenic 5:3326343 146 28
cg09720701 0.37 (±0.05) 0.06 (±0.01) HOXC4 12:54447283 7 47
cg02264990 0.35 (±0.06) 0.03 (±0.02) HOXC4 12:54447243 30 46
cg01524853 0.43 (±0.05) 0.12 (±0.03) HOXC4 12:54447807 2 51
After weight loss analysis
cg00838040 0.34 (±0.07) 0.97 (±0.03) ATP2C2 16:84446919 2 1
cg21917524 0.31 (±0.07) 0.81 (±0.04) Intergenic 11:74200334 19 10
cg24145118 0.84 (±0.07) 0.31 (±0.16) Intergenic 10:2777041 3554 7
cg12984729 0.09 (±0.03) 0.59 (±0.16) ISL2 15:76633817 3338 11
cg12437821 0.46 (±0.04) 0.05 (±0.09) Intergenic 12:114852027 185 48
cg01184975 0.53 (±0.05) 0.10 (±0.11) Intergenic 12:114852091 567 33
cg20291855 0.03 (±0.03) 0.44 (±0.11) Intergenic 4:13524143 1994 42
cg25365014 0.79 (±0.05) 0.41 (±0.05) Intergenic 5:2727713 1 89
cg16297011 0.07 (±0.04) 0.48 (±0.11) Intergenic 4:13539023 1771 40
cg21982455 0.56 (±0.04) 0.19 (±0.07) Intergenic 5:2757976 92 86
a‘Intergenic’, no gene loci annotation in Illumina manifest
bGene symbol and map position as Illumina manifest, GRCh37/hg19
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methylation assays: before weight loss (R2 = 0.91–0.98,
P = 1.2 × 10−15–8.3 × 10−25) and the single site after
weight loss (R2 = 0.97, P = 4.9 × 10−14).
Next, we sought to test the performance of these DNA
methylation biomarkers in additional, independent
samples. DNA was available for a further 15 individuals
before weight loss and 13 of these 15 individuals after
weight loss. Table 5 provides a summary of the clinical
and anthropometric data for these. Principal component
analysis (PCA) revealed a strong agreement between the
discovery and validation samples for the before weight
loss comparison, with no significant variation observed
between genders in the validation samples (Fig. 3). A
comparison of the profile of the single site (cg00838040)
in the after weight loss samples also revealed excellent
agreement between the discovery and validation samples
(Fig. 4a). Given that a SNP (rs1210757, mean minor al-
lele frequency 0.282) is located within 35 bases of
cg00838040, we looked at the pyrosequence data for this
SNP. The C/T polymorphism forms part of a CpG
dinucleotide, and, given the bisulphite conversion of the
DNA prior to pyrosequencing (because of conversion of
unmethylated cytosine to uracil, a T in the sequence is
inconclusive in terms of genotype), it was therefore
impossible to distinguish fully any genotype except CC
(where full methylation is observed). Despite this, the
pyrosequence data for the paired subcutaneous and
omental adipose samples clearly indicates that tissue
methylation at cg00838040 dominates over the
rs12102757 genotype (Fig. 4b). This is further demon-
strated in Fig. 5, which presents a more detailed summary
of the pyrosequence data for CpG methylation across the
region including cg00838040 and rs12102757. Robust tis-
sue differentiation is observed for three CpG sites flanking
cg00838040, and disruption of methylation at rs12102757,
presumably via the polymorphism, is observed.
Illumina 450K data was publically available for a num-
ber of adipose samples from lean, overweight and obese
individuals. Samples accessible through MARMAL-AID
[37] included those from six lean male individuals with
both subcutaneous and omental adipose tissue collected
at most 12 h post-mortem (GSE48472 [38]), 14 visceral
adipose (of which the greater omentum is part) sam-
ples from severely obese men with (n = 7) and without
(n = 7) metabolic syndrome (GSE54776 [39]), and six
paired subcutaneous adipose and gluteal adipose sam-
ples from lean females (GSE47513 [30]). Illumina
450K data was also available for 642 subcutaneous
adipose samples from individuals with an average
BMI of 26.7 (SD 4.9) [40] from the MuTHER (Mul-
tiple Tissue Human Expression Resource) project [41,
42] (EBI E-MTAB-1866). We looked at the methyla-
tion profile of all 11 strong discriminators from the
before (n = 10) and after (n = 1) weight loss data in
these publically available sets and observed good
agreement between the methylation profile of the
probes within a tissue type irrespective of gender
and/or obesity phenotype (Fig. 6).
In general, omental samples showed a tighter distri-
bution of methylation for a given probe than did the
subcutaneous adipose samples and for the majority of
probes a strongly hypermethylated (mean methylation
beta >0.8, cg00838040, cg17496661, cg17496661) or
hypomethylated (mean methylation beta <0.2, cg097
20701, cg02264990, cg22747076, cg03923561, cg227
47076) phenotype. Given that the biomarker analysis
was trained on data from subcutaneous and omental
adipose, it is interesting to note that the samples of
subcutaneous gluteal adipose tissue from lean females
(‘AB_Glut’, Fig. 6) showed a methylation profile similar
to that of the subcutaneous abdominal adipose
samples and clearly distinct from the omental
samples.
In addition, the performance of cg00838040 as a
biomarker to differentiate subcutaneous adipose from
omentum is clearly demonstrated in all the publically
available datasets (Fig. 6 top panel), and thus,
rs12102757 does not appear to impact this significantly.
Discussion
White adipose tissue is distributed in a number of
discrete depots around the body, which can be broadly
split into subcutaneous (including abdominal, gluteal
and femoral) and visceral (including omental, mesenteric
and epiploic) [43]. Not only is the anatomical location of
these adipose tissues different, but differences in their
function at multiple levels (physiology, structure, cell
composition, endocrinology, biochemistry, gene expres-
sion) are also observed [25, 44, 45]. Subcutaneous
adipose demonstrates particular plasticity, with adipo-
cytes, and thus tissue mass, significantly increasing in
size to store excess lipid that is thought to provide buf-
fering and protection from increased lipid accumulation
[15, 16, 46–58]. By comparison, increased risk of meta-
bolic dysfunction is associated with expansion of the
omentum [21–23]. Furthermore, it is increasingly recog-
nised that there are also differences between the differ-
ent depots of one tissue type and it is likely that each
depot has specific, nuanced function(s) [30, 49], with
developmental genes playing a key role in this [28]. Our
observations of significant differential methylation be-
tween the subcutaneous abdominal adipose and omentum
are consistent with these differences between adipose
tissue depots and with recently reported differences in
genome-wide promoter DNA methylation between these
tissues [31]. Furthermore, we observed approximately
double the number of significant differentially methylated
sites between the tissues after weight loss compared to
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Table 5 Clinical and anthropometric data for individuals in the study
Trait Before weight loss After weight loss P value (paired t test)
Discovery cohort, n = 15
Gender Female (n = 15), male (n = 0)
Age (years) 44 (±10) 45 (±10)
Weight (kg) 123.9 (±33.32) 76.2 (±15.4) 6.9 × 10−9
BMI (kg/m2) 47.6 (±11.3) 29.3 (±5.5) 3.0 × 10−7
Glucose (mmol/L) 5.5 (±1.2) 4.6 (±0.6) 0.035
Insulin (pmol/L) 176.2 (±168.1) 33.4 (±19.3) 0.011
HbA1c % (DCCT)a 6.0 (±0.6) 5.5 (±0.5) 0.036
Triglycerides (mmol/L) 1.6 (±0.7) 1.0 (±0.3) 0.01
Total cholesterol (mmol/L) 5.3 (±0.8) 4.6 (±0.6) 9.0 × 10−4
HDL (mmol/L) 1.4 (±0.4) 1.8 (±±0.9) 0.167
LDL (mmol/L) 3.2 (±1.1) 2.6 (±0.6) 0.018
Systolic blood pressure (mmHg) 135 (±18) 115 (±9) 0.006
Diastolic blood pressure (mmHg) 78 (±13) 73 (±9) 0.122
Time (months) 17.6 (±6.9)
In-house validation cohort, n = 15b
Gender Female (n = 6), male (n = 9)
Age (years) Female 45 (±6) Female 47 (±6)
Male 47 (±10) Male 49 (±10)
Weight (kg) Female 118.7 (±13.9) Female 77.5 (±9.7) 1.9 × 10−4
Male 156.2 (±17.3) Male 95.8 (±12.4) 3.7 × 10−5
BMI (kg/m2) Female 43.8 (±4.0) Female 28.9 (±2.9) 2.1 × 10−4
Male 50.3 (±7.6) Male 30.7 (±2.6) 1.0 × 10−4
Glucose (mmol/L) Female 5.8 (±1.8) Female 4.7 (±0.4) 0.169
Male 5.8 (±0.9) Male 5.0 (±0.5) 0.038
Insulin (pmol/L) Female 69.7 (±39.7) Female 25.2 (±17.1) 0.017
Male 184.0 (±72.0) Male 49.5 (±29.6) 0.013
HbA1c % (DCCT)a Female 6.4 (±1.6) Female 5.5 (±0.6) 0.148
Male 6.2 (±0.5) Male 5.5 (±0.4) 0.163
Triglycerides (mmol/L) Female 1.3 (±1.0) Female 0.8 (±0.3) 0.121
Male 1.7 (±1.0) Male 1.2 (±0.3) 0.039
Total cholesterol (mmol/L) Female 4.6 (±1.0) Female 4.9 (±1.5) 0.677
Male 5.0 (±1.1) Male 4.3 (±4.3) 0.092
HDL (mmol/L) Female 1.4 (±0.2) Female 1.5 (±0.2) 0.042
Male 1.1 (±0.1) Male 1.5 (±0.4) 0.038
LDL (mmol/L) Female 2.6 (±0.8) Female 3.0 (±1.4) 0.548
Male 3.1 (±0.9) Male 2.3 (±0.5) 0.055
Systolic blood pressure (mmHg) Female 123 (±11) Female 112 (±13)
Male 127 (±24) Male 121 (±14)
Diastolic blood pressure (mmHg) Female 76 (±6) Female 69 (±11)
Male 77 (±6) Male 74 (±12)
Time (months) Female 19.8 (±5.5)
Male 17.4 (±6)
Data are expressed as means ± standard deviation. Paired adipose samples were available for all 15 before weight loss and for 13/15 after weight loss
aHbA1c is reported as % using DCCT (Diabetes Control and Complications Trial) units
bBlood pressure data was not available for samples in the validation cohort
Macartney-Coxson et al. Clinical Epigenetics  (2017) 9:48 Page 12 of 21
Dim 1 (88.95%)
D
im
 2
 (
3.
05
%
)
−1
0
1
−4 −2 0 2 4
AB_Dis
AB_val
OM_Dis
OM_val
Cohort
−4 −2 0 2 4
Female
Male
Gender
−4 −2 0 2 4
ABOM
Tissue
Fig. 3 PCA of the top 10 CpG sites from the before weight loss analysis. Analysis was performed on pyrosequence data. Tissue type is indicated
by OM (omentum) and AB (subcutaneous abdominal adipose), with Dis indicating the discovery and val the validation samples
Fig. 4 Pyrosequence data for cg00838040 in a the discovery and validation samples and b the rs1202757 genotype. Percent methylation values
(Y axis) obtained from pyrosequence data are presented for subcutaneous adipose (AB, turquoise) and omentum (grey, OM). A. Methylation values
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beforehand. This may indicate a remodelling of adipose
tissue after weight loss (and/or gastric bypass itself ) to
reflect a greater distinction between the tissues seen in a
non-obese environment. Looking at Fig. 6 and the
subcutaneous abdominal adipose samples from females
before (AB_pre) and after (AB_post) weight loss in com-
parison to publically available subcutaneous abdominal
adipose from lean females (AB_SC), 6 of 10 probes show a
methylation profile for the post-weight loss sample more
similar to that of the lean females, providing some support
for the conjecture that the DNA methylome is reflecting a
more ‘normal’ state after weight loss. Our study sampled
whole adipose tissue, which is a mixture of cell types.
Therefore, the methylation differences may reflect both
varying complements of cell types within the different tis-
sues investigated and the fact that cell type proportions
may vary significantly within adipose tissue before and
after weight loss. A possibility, reflected in our observation
of almost half the number of significant differentially
methylated sites before weight loss compared to after, is
that the adipose tissues at this time point may well contain
a greater proportion of inflammatory cells that serve to
mask the difference between the tissues. In line with this
suggestion, we observed a DMR unique to the before
weight loss comparison within HOTAIRM1, which was
identified as a long non-coding RNA transcribed from the
region between HOXA1 and HOXA2 expressed specific-
ally in cells of myeloid lineage [50]. Our previous study
examining intra-adipose tissue DMRs before and after
weight loss and using publically available DNA methyla-
tion data for whole blood as a proxy for inflammatory cells
also highlighted this possibility [32]. Enrichment analyses
of the genes mapping to the 722 DMRs observed in the
tissue comparisons at both time points highlighted the
role of transcriptional regulation and homeobox genes in
differences between tissues. We reasoned that these are
likely to represent developmental (and other) epigenetic
differences that are hard-wired and critical to the function
of the two tissues, because they remained consistent after
the significant weight loss and other physiological and
metabolic changes associated with gastric bypass. A
recent study identified six adipose depot specific
genes (SORBS2, HAND2, PPARG, HOXC6, CD36 and
CLDN1) using genome-wide promoter DNA methylation
Fig. 5 Summary of methylation across the genomic region of ATP2C2 interrogated by pyrosequencing. a UCSC genome browser track region.
Yellow blocks indicate CpG sites interrogated, black box indicates the location of SNP rs12102757 and orange box indicates the position of
cg00838040. b Pyrosequence methylation data for the five CpG sites sequenced in the region. AB abdominal adipose, represented by pink boxes,
OM omental adipose, represented by blue boxes
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and transcriptome analysis of subcutaneous adipose and
omentum from obese and lean individuals [31]. Consistent
with this, we observed differentially methylated CpG loci
in SORBS2, HAND2, HOXC6 and CLDN1. When we
looked for correlations between changes in methylation
between tissues and changes in clinical parameters (for
sites showing significant differential methylation at both
time points), we saw strong correlations for Δbeta after
weight loss and ΔHDL for CpG sites within SORBS2
(cg04348265, r = 0.83), CLDN1 (cg03623835, r = −0.86)
and the HOXC cluster (HOXC4, HOXC5, HOXC6;
cg00506343, r = −0.92). In addition, we observed a strong
correlation between the Δbeta of four CpG sites in ISL2
and change in HDL. Little is known about the func-
tion of ISL2, although the related ISL1 gene is in-
volved in the embryogenesis of pancreatic islet cells
[51, 52] and its homology to ISL1 implies a potential
role as an enhancer of insulin gene expression [53,
54]. Given this further investigation of the role of
ISL2 in adipose tissue biology and potentially insulin
sensitivity is warranted.
Not only did we see clear differences in the methyla-
tion of homeobox genes, which are known to have a role
in adipose tissue development and differentiation [55],
but we also observed variability in other genes with a
role in development. WT1 is involved in the mesothelial
origin of visceral adipose [29], and gene expression dif-
ferences between subcutaneous and visceral adipose
have also been reported [56]. Consistent with this, we
observed differential methylation of a number of CpG
sites in the body of WT1 (Table 3). Traditionally, DNA
methylation within promoter regions has been associ-
ated with decreased transcription; however, the picture
now seems considerably more complicated, with DNA
Fig. 6 Methylation of the robust discriminatory probes from each analysis in publically available adipose tissue data. Box plots of the methylation
beta values (Illumina 450K analysis) for cg00838040 and the top 10 probes from the before weight loss analysis. Subcutaneous adipose is
prefaced AB in all cases and omental or visceral adipose OM. Data from the current study is shaded grey with before weight loss samples
indicated by ‘pre’ (i.e. AB_pre and OM_pre) and after weight loss shown as AB_post and OM_post. Publically available data is as follows: AB_Glut
and AB_SC indicate paired gluteal and abdominal subcutaneous samples, respectively, from normal weight females (GSE47513 [35]); AB_PM and
OM_PM indicate data from six paired subcutaneous adipose and omentum samples, respectively, taken 12 h post-mortem from normal-weight
males (GSE48472 [43]); AB_twin indicates subcutaneous abdominal adipose data from 642 individuals from the MuTHER twin study [46, 47]
(EBI E-MTAB-1866) who had an average BMI of 26.7 (±4.9) [45]
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methylation within the gene body affecting expression
and also alternative splicing [57–59]. Therefore, given
our identification of differentially methylated CpG sites
within the body of WT1 using both our analytical ap-
proaches, and this gene’s role in development and cancer
biology in particular, further investigation with regard to
different transcriptional isoforms or regulatory non-
coding RNA transcripts may be warranted. We also note
that a DMR unique to the after weight loss comparison
was located in WTAPP1 (Wilms tumour 1-associated
protein pseudogene).
If significant differentially methylated loci that overlap
between the two time points (before and after gastric
bypass-associated weight loss) are indicative of hard-
wired developmental (and functional) differences be-
tween the tissues, then we reasoned that loci ‘unique’ to
each time point might provide insight(s) into the dys-
function/dysregulation that occurs in obesity and/or the
subsequent effects of gastric bypass and significant
weight loss.
Enrichment for gene targets of miR141 and miR200
was observed for the before weight loss comparison.
These two miRNA have been reported to silence IGF2
in mouse placental development [60], and miR141 has
been shown to have a role in epithelial-mesenchymal
transition in kidney epithelial cells through the downreg-
ulation of HIPK2 [61]. Oger et al. [62] observed dysregu-
lation of miR200a and b in epididymal white adipose but
not inguinal white adipose (surrogates for visceral and
subcutaneous adipose in humans, respectively) in ob/ob
and high-fat-diet mice. Expression was reduced in obese
compared to control mice, and reduced expression was
also observed in visceral, but not subcutaneous, adipose
from obese type 2 diabetics compared to lean controls in
humans. Furthermore, they saw changes in the relative
levels of miR200a and b in preadipocytes and adipocytes
in obese vs control mice, suggesting a potential role for
miR200 in adipocyte differentiation. Thus, miR200 and
miR141 are potentially involved in cell development and
differentiation and in particular perturbations of visceral
adipose associated with obesity. Our data are consistent
with this and suggest a role for DNA methylation.
The homeobox gene, HOXD8, and the HOX-related
long-noncoding RNA, HOTAIRM locus, may also war-
rant further investigation with regard to the dysfunction
of adipose tissue in severe obesity, as DMRs in these two
loci were only observed in the before weight loss com-
parison. As eluded above, the presence of a DMR in
HOTAIRM1 may be indicative of a greater proportion of
inflammatory cells before weight loss. Other DMRs were
seen at both time points within the HOXD cluster
(HOXD 3, 4, 9, 10). HOXD8 lies between HOXD3-4 and
HOX9-10, raising the possibility that dysregulation
between these two regions of the cluster is occurring.
At the after weight loss time point, DMRs in mTOR
and RPTOR were observed. The mTOR signalling path-
way has a fundamental role in adipose tissue function,
although major questions remain regarding how this
pathway is regulated in specific tissues (for a review, see
[63]). Given the central role of the mTOR pathway in
regulating/responding to environmental cues (such as
nutrients, growth factors and stress), one would antici-
pate a regulatory role for epigenetics, and our data adds
weight to the evidence that DNA methylation plays a
part, at least, in adipose tissue.
A second aim of this study was to test the ability of
our combinatorial approach to identify loci that distin-
guish between groups. We were motivated by (a) the
hypothesis that because the two different adipose tissues
had purportedly different developmental origins, they
would have a clear epigenetic/DNA methylation signa-
ture and therefore present an excellent dataset to test
our methodology and (b) the fact that the approach
complements and extends standard statistical techniques
for differential analysis. This novel method harnesses the
power of mathematical abstraction via graph-theoretical
techniques and gains efficiency and scalability through
high-performance algorithms and implementations.
Thus, unlike traditional differential analyses based on
mere pairwise comparisons, a combinatorial approach
interrogates the entire solution space of methylation
sites and filters out all but a small subset of near-optimal
discriminators (aka biomarkers).
The origins of this approach began with our work on
combinatorial methods for the interpretation of gene
array expression data for pulmonary adenocarcinoma
[64]. While mRNA and DNA methylation data are both
numeric and share many similarities, there are also some
important differences; for instance the data points and
thus file sizes were roughly an order of magnitude larger
for the DNA methylation data. Therefore, the methods
need to be both scalable (increased dimensionality) and
vigilant (correction for potential false positives). While
the approach concentrates mainly on extreme values,
caution must be given to distributional concerns, since
traditional methods very often assume normality, while
probe scores on the Illumina 450K BeadChip are
bimodal. Because our toolchain employs both graph-
theoretical algorithms and statistical techniques, sample
size is sometimes an additional concern. The addition of
a dominating set filter, as described here, seems particu-
larly effective in this regard. Moving forward, we are
currently incorporating machine learning in the form of
neural net classifiers into our analytical suites, but that
topic is beyond the scope of the work presented here.
The utility of combinatorial approach is demonstrated
by our identification of CpG sites that robustly differen-
tiate between white adipose tissue types. These robust
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discriminators were filtered to reveal 10 CpG sites be-
fore weight loss and a single site after weight loss, which
strongly separated the adipose tissue depots. Additional
confidence in our results is provided by an excellent
overlap between the pyrosequence methylation profiles
of the 11 CpG sites in the discovery and validation
cohorts (Figs. 3 and 4) and from publically available sub-
cutaneous and omental adipose Illumina 450K data from
lean, overweight and obese individuals (Fig. 6). With
these results, we are confident that combinatorial
methods are both powerful and applicable to DNA
methylation data.
While there is no clinical utility in a marker to differ-
entiate subcutaneous and omental adipose, our study
provides further support for the potential of DNA
methylation as a biomarker. As such, we believe future
work to translate our combinatorial approach to the
detection of clinically applicable DNA methylation
biomarkers is warranted and may have particular merit
for situations in which robust differentiators are still ur-
gently required. Furthermore, because epigenetic mecha-
nisms are dynamic and as such potentially reversible,
these types of analyses may also highlight innovative
new avenues for clinical treatment. Such analyses should
take account of practicability concerns such as ease of
sample/tissue collection and whether there is a biological
argument for potential DNA methylation differences be-
tween sample groups. Depending on the environmental
stimuli influencing the epigenetic modification, it may
be that, in some cases, a tissue- and phenotype-specific
change is also reflected in blood (a more tractable sam-
ple for routine analysis). For instance, a DNA methyla-
tion change within the HIF3A gene was recently found
to be associated with BMI. On further investigation, the
authors discovered the same methylation change asso-
ciated with BMI in subcutaneous adipose (a phenotype-
relevant tissue) but not skin [40].
It is striking that a single CpG site identified from the
after weight loss comparison (cg00838040) appears to
differentiate between tissue types from both lean and
obese individuals (Figs. 2f, 4 and 5). This site was located
in the body of ATP2C2, a gene that encodes a
manganese-transporting calcium ATPase SPCA2 prima-
rily located in the Golgi membrane. The CpG site
(cg00838040) was located within a binding site for tran-
scription factor CEBPB, which plays a role in adipogene-
sis and inflammatory responses (for a review, see [65]).
A previously unreported transcript of ATP2C2, termed
ATP2C2c, was recently identified in mice [66]. Tran-
scription of this isoform is initiated in intron 23 and
under epigenetic (histone modification) and transcrip-
tion factor (MIST1) control. Expression of ATP2C2 ap-
peared to be mostly restricted to pancreatic acinar cells
in mice, which plays a crucial role in the regulation of
Ca2+ associated with the control of secretion of digestive
enzymes [66]. While the intronic location of the tran-
scription start site for ATP2C2c is some 30 kb away from
cg00838040 and the CEBPB binding site, it raises the
possibility that other, yet to be identified, isoforms of
ATP2C2 exist, which may have important tissue-specific
functions. Furthermore, when we looked at expression
of ATP2C2 in the GTEx Portal, levels of mRNA in
subcutaneous adipose and omentum were minimal. If
expression of ATP2C2 (and/or a specific isoform) is
important in adipose tissue differentiation and develop-
ment, it may be that its expression occurs early in deve-
lopment, rather than in ‘mature’ tissue (most likely
represented in the database). Thus, while a DNA methy-
lation mark may persist, any related mRNA signature
may not. While we were unable to detect any significant
correlations between changes in ATP2C2 methylation
and clinical traits, our power was limited by the small
sample size, and further investigation in a larger cohort
is warranted.
The CpG site in ATP2C2 interrogated by cg00838040
was effectively completely hypermethylated in all the vis-
ceral adipose tissues we examined, which almost surely
reflects its discriminatory power. As such, it may be that
one selection criterion that could be applied for triaging
potential DNA methylation biomarkers is whether they
are effectively either completely methylated or unmethy-
lated in one group. This idea is further supported by the
data for the other robust discriminators shown in Fig. 6.
All but 2 of 11 probes (cg02245004 and cg09400037)
show a very tight hyper- or hypomethylation profile in
one of the tissues across all samples groups, cg24376776
in subcutaneous adipose and 8 probes in omentum.
While the discovery phase of our study was limited in
size and gender (n = 15 females), 11 CpG sites which
robustly separated subcutaneous and omental adipose
were validated in a small, independent cohort of mixed
gender (n = 15 before weight loss, n = 13/15 after weight
loss, n = 9 males, n = 6 females) and in publically avai-
lable datasets (n = 681 subcutaneous adipose and n = 33
omentum, mixed gender). This replication may well
reflect both the power of a paired analysis and the
distinctive DNA methylome signature of the two adipose
tissue depots investigated. The small sample size will
have significantly affected our ability to detect correla-
tions between changes in DNA methylation between
tissue and clinical parameters. As such, our observation
of strong correlations (r > 0.7, P ≤ 0.001) highlights
potential candidates for further investigation in larger
cohorts. Our study analysed the DNA methylome of adi-
pose tissue as a whole. However, adipose is composed of
a mixed cell population that varies according to tissue
type and includes adipocytes (20-40%), fibroblasts, prea-
dipocytes, stem cells and immune cells, all of which are
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fundamental to its function [67]. Furthermore, DNA
methylation (and other ‘global’) analyses can be con-
founded by cell mixtures within a sample. While there is
intense work to develop algorithms to deal with such
‘admixtures’ [68–70], they have been applied to blood
cell mixtures to date, and we did not have any cell
type information/distribution information for the ar-
chived frozen tissue used in this study. It will be im-
portant to investigate the robust adipose tissue
discriminators identified here in the different cell
types within adipose tissue, for instance to determine
whether cg00838040 differentiates between subcutane-
ous adipose and omental preadipocytes. RNA was not
available for us to perform a transcriptomic analysis
of the adipose tissue in parallel with the DNA methy-
lation investigation. Given that DNA methylation is
known to play a role in regulating gene expression,
this highlights a potential avenue for future research,
targeting some of the candidate loci identified in this
study in particular.
Conclusions
This study is, to our knowledge, the first to report a
genome-wide DNA methylation comparison of subcuta-
neous abdominal and omental adipose before and after
weight loss. We also describe the application of novel
combinatorial algorithms to identify robust DNA methy-
lation signatures that strongly differentiate between
these two adipose tissue depots. Only one CpG locus in
ATP2C2 was required to distinguish between the two tis-
sues in our study cohort, validation samples and publi-
cally available data from both lean and obese individuals.
This illustrates the extreme potential power of DNA
methylation as a biomarker and the overall utility of our
biomarker detection approach. This work provides
additional information relevant to both the development
and differentiation of different adipose tissues and the
potential dysfunction of these processes in obesity.
Methods
Sample inclusion
The cohort included individuals who underwent gastric
bypass by a single surgeon at Wakefield Hospital,
Wellington, New Zealand, and who returned for a
second operation (incisional hernia repair (n = 24), inci-
sional hernia repair and abdominoplasty (n = 2), silastic
ring removal (n = 2) or Roux loop lengthening (n = 1)).
Clinical and anthropometric data for the discovery co-
hort (n = 15 as previously described [32]) and validation
cohort (n = 15, samples available for all 15 before weight
loss and 13/15 after weight loss) are presented in Table 5.
Four individuals in the discovery cohort had type 2 dia-
betes at the time of the first surgery (two males and two
females), as did four in the validation cohort (two males
and two females). Adipose tissue samples were taken at
the time of surgery, immediately snap frozen in liquid
nitrogen and stored at −80 °C.
DNA extraction
DNA was extracted from approximately 100 mg of tissue
using a QIAamp DNeasy Tissue Kit (Qiagen) as per the
manufacturer’s protocol and included a 3-h initial lysis
step and RNase treatment. Nanodrop quantitation of
DNA was performed.
DNA methylation 450K Illumina BeadChip
Analysis of Illumina 450K data from subcutaneous
abdominal and omental adipose before and after gastric
bypass and significant weight loss was carried out on
previously generated data [32], which is available from
the EBI ArrayExpress database (E-MTAB-3052).
DNA methylation pyrosequencing
DNA samples were sent to EpigenDX (USA). Pyrose-
quencing assays were designed, optimised and per-
formed by EpigenDX with both pyrograms and assay
result data supplied. Loci targeted for analysis were as
follows (as per Illumina 450K probe identification):
cg02245004, cg03923561, cg22747076, cg09400037,
cg24376776, cg11797364, cg17496661, cg09720701,
cg02264990, cg01524853, cg00838040. Sufficient DNA
was available from all 15 individuals in the core
discovery cohort (Table 5) for samples taken before
weight loss, whereas samples from only 9 of 15 were
available for the after weight loss comparison.
Biomarker analyses
We applied a combination of statistical tools and graph-
theoretical algorithms to identify putative biomarkers
indicative of tissue type. The general approach we
employed can be traced back to our work on transcrip-
tomic data and differential analysis toolchains [64].
Additional technical details can be found in [71, 72].
Sites are initially scored by maximizing the difference
between intra-class median values, less the sum of the
standard deviations within each class. A finite, simple,
undirected graph is then constructed, treating indivi-
duals as vertices and weighting edges by a similarity
metric using the highest scoring sites. The graph is
thresholded, and cliques are isolated to check for homo-
geneity. If this step is successful, a parameterised imple-
mentation of red/blue dominating set is then employed
to eliminate sites best covered by others [73]. Specifically,
we first calculated a merit value for each methylation site,
based on the site’s apparent utility in separating sample
sets. We then employed graph-theoretical algorithms
(primarily clique and dominating set) to identify those
sites that best cover others and a Wilcoxon signed rank
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test to apply a P < 0.001 threshold. To estimate the poten-
tial effectiveness of this list, pairwise inter-sample scores
were calculated using site and methylation values. If suc-
cessful, homogeneous pairs should score highly, while in-
homogeneous pairs should not, thus providing the desired
separation.
Data analyses
Statistical analyses relied on R [74]; combinatorial
algorithms were performed in C. Quality control,
normalisation and differential methylation analyses of
Illumina 450K DNA methylation array data were
performed as outlined previously [32]. DMRs were
identified with the DMRcate package using default
settings [35]. DMR overlaps were determined using
GRanges intersect. All correlation analyses were per-
formed using the base R cor function for Pearson’s
correlation and the base R linear model (lm) function.
PCA was performed using the FactoMineR package
[75]. Publically deposited Illumina 450K data was
obtained using the MARMAL-AID R package [37] or
from the EBI ArrayExpress database. Gene enrich-
ment analyses were performed using the ToppGene
Suite [76]. Enrichment was classified as significant at
a Bonferroni-adjusted P ≤ 0.05.
Additional files
Additional file 1: Annotated data for the 3239 significantly differentially
methylated CpG sites between omental and abdominal subcutaneous
adipose before weight loss. Illumina probe ID, gene name, gene region
and chromosomal location (as Illumina 450K manifest) are shown along
with methylation statistics. OM_mean_beta and AB_mean_beta present
mean beta values for omental (OM) and abdominal subcutaneous (AB)
adipose, respectively. We also indicate which CpG sites overlap with
those observed in the post-weight loss analysis (Overlap_CpG), whether
the change in methylation between SC and OM is greater at the post-
weight loss time point (Greater_Δbeta_Post) and whether the CpG site
was observed as differentially methylation before vs after weight loss in
AB (Overlap_AB_Benton_etal) in our previous study [37]. (No overlap with
the previous OM comparison was observed). (CSV 263 kb)
Additional file 2: Annotated data for the 3239 significantly differentially
methylated CpG sites between omental and abdominal subcutaneous
adipose after weight loss. Illumina probe ID, gene name, gene region
and chromosomal location (as Illumina 450K manifest) are shown along
with methylation statistics. OM_mean_beta and AB_mean_beta present
mean beta values for omental (OM) and abdominal subcutaneous (AB)
adipose, respectively. We also indicate which CpG sites overlap with those
observed in the post-weight loss analysis (Overlap_CpG), whether the
change in methylation between SC and OM is greater at the post-weight
loss time point (Greater_Δbeta_Post) and whether the CpG site was
observed as differentially methylation before vs after weight loss in AB
(Overlap_AB_Benton_etal) and OM (Overlap_OM_Benton_etal) in our
previous study [37]. (CSV 637 kb)
Additional file 3: Annotated data for the 784 significant DMRs
between omental and abdominal subcutaneous adipose before
weight loss. Chromosomal location including DMR start and finish,
number of CpG sites, gene symbol and level of differential
methylation are included. (CSV 43 kb)
Additional file 4: Annotated data for the 1129 significant DMRs
between omental and abdominal subcutaneous adipose after weight
loss. Chromosomal location including DMR start and finish, number
of CpG sites, gene symbol and level of differential methylation are
included. (CSV 63 kb)
Additional file 5: Enrichment results for genes mapping to DMRs only
observed in the before weight loss analysis. All pathways passing
Bonferroni correction (P ≤ 0.05) are shown. (XLSX 8 kb)
Additional file 6: Enrichment results for genes mapping to DMRs only
observed in the after weight loss analysis. All pathways passing
Bonferroni correction (P ≤ 0.05) are shown. (XLSX 12 kb)
Additional file 7: Enrichment results for genes mapping to DMRs
observed in both the before and after weight loss analyses. All pathways
passing Bonferroni correction (P ≤ 0.05) are shown. (XLSX 19 kb)
Additional file 8: Enrichment results for genes mapping to DMRs
observed in both the before and after weight loss analyses, for which the
methylation difference between tissues was greater after weight loss. All
pathways passing Bonferroni correction (P ≤ 0.05) are shown. (CSV 7 kb)
Additional file 9: Summary of Pearson’s correlation data passing a
P ≤ 0.001 threshold for comparison of Δbeta (subcutaneous adipose vs
omentum) and Δclinical trait (before vs after weight loss). (XLSX 19 kb)
Additional file 10: Annotated data for the 4900 CpG sites with a
positive merit score in the combinatorial algorithm analysis before
weight loss analysis. Illumina probe ID, gene symbol, gene region and
chromosomal location (as Illumina 450K manifest) are shown along with
methylation statistics. OM_mean_beta and AB_mean_beta present mean
beta values for omental (OM) and abdominal subcutaneous (AB) adipose,
respectively. Merit score and ranking are also provided. (CSV 310 kb)
Additional file 11: Annotated data for the 8624 CpG sites with a
positive merit score in the combinatorial algorithm analysis after weight
loss. Illumina probe ID, gene symbol, gene region and chromosomal
location (as Illumina 450K manifest) are shown along with methylation
statistics. OM_mean_beta and AB_mean_beta present mean beta values
for omental (OM) and abdominal subcutaneous (AB) adipose,
respectively. Merit score and ranking are also provided. (CSV 655 kb)
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